# DYNASTY-Breast02 (NCT06018337)

> A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06018337
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: DualityBio Inc.
- Conditions: Metastatic Breast Cancer
- Interventions: DB-1303/BNT323; Capecitabine; Paclitaxel; Nab-paclitaxel
- Enrollment: 541
- Primary outcome: Progression-free survival (PFS) in the HR+, HER2-low population

## Indexed commentary on DYNASTY-Breast02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 2
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dynasty-breast02-nct06018337

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06018337", "email": "<work email>"}; the inbox owner confirms by the emailed link.